New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCartalax vs 5-Amino-1MQ

Cartalax vs 5-Amino-1MQ

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cartalax
Fat Loss & Metabolic
5-Amino-1MQ
Summary
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
Half-Life
Short (minutes); gene-regulatory effects are sustained
Estimated 4–8 hours
Admin Route
SubQ, Oral
Oral
Research
Typical Dose
10 mg per day
50–100 mg
Frequency
Daily for 10–30 days
Once to twice daily
Key Benefits
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
  • Raises intracellular NAD+ levels
  • Directly targets adipose tissue for fat reduction
  • Reduces fat cell size and differentiation
  • Increases basal metabolic rate
  • SIRT1 activation for metabolic regulation
  • No stimulant cardiovascular side effects
  • Synergistic with intermittent fasting and caloric restriction
  • May have anti-aging metabolic benefits
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
  • Generally well-tolerated in available studies
  • Mild GI discomfort (rare)
  • Limited long-term human data
Stacks With